BCG-medac is intended for intravesical use following reconstitution. For instructions on reconstitution of the BCG-medac suspension before administration, see section 6.6.

Introduction: Adjuvant treatment with endovesical BCG instillations after resection of a bladder urothelial tumor remains the gold standard for intermediate- or high-risk non-muscle-invasive …

Adjuvant treatment with endovesical BCG instillations after resection of a bladder urothelial tumor remains the gold standard for intermediate- or high-risk non-muscle-invasive tumors. However, …

BCG-medac stimulates the immune system and is used to treat several types of cancer in the urinary bladder. It is effective if the cancer is limited to the cells lining the inside of the bladder …

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative …

1993年5月6日 · BCG-medac regt das Immunsystem an und wird zur Behandlung verschiedener Arten von Harnblasenkrebs angewendet. Es ist wirksam, wenn der Krebs nur die Zellen …

leaflet. BCG-medac contains weakened (attenuated) Mycobacterium bovis bacteria with low infectious potential. BCG-medac stimulates the immune sy. tem and is used to treat bladder …

BCG-medac is introduced into the bladder by means of a catheter and at low pressure. The instilled BCG-medac suspension must remain in the bladder for a period of 2 hours if possible. …

BCG‑MEDAC stimule le système immunitaire et il est utilisé pour traiter plusieurs types de cancer de la vessie. Il est efficace si le cancer est limité aux cellules qui tapissent la paroi interne de …

2024年7月5日 · BCG-medac Powder and solvent for intravesical suspension - Summary of Product Characteristics (SmPC) by medac Pharma LLP